Versions Compared

Old Version 84

changes.mady.by.user Alex Pearce

Saved on

compared with

New Version Current

changes.mady.by.user Alex Pearce

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Image RemovedImage Added


Project Scope

  • Define role of QTLs in QbD, in particular the relationship to CTQs (Critical to Quality Factors), Estimands and continuous quality improvement (CQI)
  • Discuss the use of QTLs in Early Development/small studies, bio equivalence and complex designs
  • Discuss examples of how to define QTLs, different methodologies and different parameters in use across the industry
  • Discuss difficulties and challenges of implementation of QTLs
  • Examine role of QTLs as part of the of the lessons learned (RCA) feedback loop



Project LeadsEmail
Michael Walega (Bristol Myers Squibb)
michael.walega@bms.com
Chris Wells
(
, Roche
)
chris.wells.cw1@roche.com
Mireille Lovejoy, GE HealthcareMireille.lovejoy@gehealthcare.com
Alex Pearce
(
, PHUSE Project
Coordinator) 
Assistant 

Alexandra@phuse.global


Status
colourBlue
titleCurrent Status
Q4 2023

  • Continuing to work on their White Paper



Objectives & DeliverablesTimelines
Release of draft White Paper Q3 2022
Publish White PaperQ3 2023

Status
colourBlue
titleCurrent Status
Q2 2023

  • Survey Instruments completed and shared within industry 
  • Collected responses from 15 companies 
  • Team is evaluating results and preparing for the delivery of a White Paper 
Project MembersOrganisationAlicja MarkGenmabAndrew McGowanRHO WorldAndrzej KinasiewiczAstraZenecaAnne LawrenceAbbVieAnsalan StewartFDAArati TodkarTCSArseny KhaplanovParexelBarbara SeiderZealand Pharma Chonna CampbellUnither PharmaceuticalsCrupa KurienPfizerDebra JendrasekDSIHeidi HoffmanGenentechJennifer KrohnPPDJean MulindeFDAJulie AppelNovo NordiskKaren BleichFDAKate TomlinsonPRISMKatherine TaylorMerckKevin DouglassDSIKingsley KaluarachchiGE HealthCare Linda Del PaggioGenentechLukasz BojarskiAstraZenecaLynne CesarioPfizerMary ArnouldAstellasProject MembersOrganisationMireille LovejoyRocheMonika MoerschBoehringer-IngelheimMukesh BabuIndustryNathalie Van BorrendamJanssen Research & Development Nick Wells Syneos Health Paul BrownDanish Medicines AgencyPriti GuptaPfizerShalaka GadhaveTCSSheetal ChandaranaRocheSteve Young CluePointsSteven GilbertPfizerYu Meng Merck





Problem Statement

QTLs -  the role they play in defining quality within the QbD framework, their relationship to Critical to Quality factors, associated methodologies and the interpretation of them have not been fully defined in clinical development, in particular where early development/small studies, bio equivalence studies and complex designs are concerned.

Problem Impact

This will impact the whole clinical development process and allow the move away from perfection to a defined and achievable quality, from which continuous quality improvement can begin.



Terminology Example:

  • Target Product Profile (TPP)
    • Patient wants extended dosing from current BD product on market
  • Critical Quality Attribute (CQA)
    • Once a day dosing
  • Critical to Quality Factor (CTQ)
    • In early stage trials drug levels shown at 24 hours
    • In Phase 2-3 demonstrate efficacy
  • Quality Tolerance Limit
    • Pre-define what will be acceptable limits for acceptance
      • These QTL's will change at different stages